Skip to Main Content

Author Details

John L Humm
Memorial Sloan Kettering Cancer Center
1986
254
64
PMIDPaper TitleJournal TitlePublished Year
37712994Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.Eur J Nucl Med Mol Imaging2024
36357182Reply: Dosimetry in Radiopharmaceutical Therapy.J Nucl Med2023
37652541Lesion Dosimetry for [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.J Nucl Med2023
37244631Activation of STING in Response to Partial-Tumor Radiation Exposure.Int J Radiat Oncol Biol Phys2023
37171634The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.Eur J Nucl Med Mol Imaging2023
37201655Yttrium-90 Activity Quantification in PET/CT-Guided Biopsy Specimens from Colorectal Hepatic Metastases Immediately after Transarterial Radioembolization Using Micro-CT and Autoradiography.J Vasc Interv Radiol2023
36853490Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma.J Neurooncol2023
36759197Radioimmunoscintigraphy and Pretreatment Dosimetry of <sup>131</sup>I-Omburtamab for Planning Treatment of Leptomeningeal Disease.J Nucl Med2023
34993893F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation.J Nucl Cardiol2022
35641607Correction to: Optimizing <sup>90</sup>Y Particle Density Improves Outcomes After Radioembolization.Cardiovasc Intervent Radiol2022
35459960Optimizing <sup>90</sup>Y Particle Density Improves Outcomes After Radioembolization.Cardiovasc Intervent Radiol2022
35446848SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans.PLoS One2022
36371226Phase 1 study of intraventricular <sup>131</sup>I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.J Hematol Oncol2022
36192334Dosimetry in Radiopharmaceutical Therapy.J Nucl Med2022
36258098TriDFusion (3DF) image viewer.EJNMMI Phys2022
35257504Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor.Pharmacol Res Perspect2022
34857661Biodistribution and Radiation Dosimetry of Intraperitoneally Administered <sup>124</sup>I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.J Nucl Med2022
32646874Predicting Gemcitabine Delivery by <sup>18</sup>F-FAC PET in Murine Models of Pancreatic Cancer.J Nucl Med2021
33855685Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors.EJNMMI Res2021
34250566Optimizing reconstruction parameters for quantitative <sup>124</sup>I-PET in the presence of therapeutic doses of <sup>131</sup>I.EJNMMI Phys2021
34359810Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas.Cancers (Basel)2021
34109515A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.Breast Cancer Res Treat2021
33429428Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.J Natl Cancer Inst2021
33309909Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy.Int J Radiat Oncol Biol Phys2021
33277396Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.J Nucl Med2021
33047248IntraOmmaya compartmental radioimmunotherapy using <sup>131</sup>I-omburtamab-pharmacokinetic modeling to optimize therapeutic index.Eur J Nucl Med Mol Imaging2021
33073651Patients as objects: Medical student perspectives on the patients as teachers program.Med Teach2021
31601700Pharmacokinetic Assessment of <sup>18</sup>F-(2<i>S,</i>4<i>R</i>)-4-Fluoroglutamine in Patients with Cancer.J Nucl Med2020
31865407<sup>18</sup>F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases.Eur J Nucl Med Mol Imaging2020
31862801<sup>11</sup>C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series.J Nucl Med2020
32066626Targeted Brain Tumor Radiotherapy Using an Auger Emitter.Clin Cancer Res2020
33226505KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liver.EJNMMI Res2020
33137396Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures.Radiother Oncol2020
32298392Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.PLoS One2020
27171605Copper-64 trastuzumab PET imaging: a reproducibility study.Q J Nucl Med Mol Imaging2019
31405921Biodistribution and Dosimetry of Intraventricularly Administered <sup>124</sup>I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.J Nucl Med2019
31117485Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.Mol Pharm2019
31053681Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.J Nucl Med2019
30879172Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.J Neurooncol2019
30850488Assessment of Simplified Methods for Quantification of <sup>18</sup>F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.J Nucl Med2019
30488098Prognostic value of baseline metabolic tumor volume measured on <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.Eur J Nucl Med Mol Imaging2019
30342090An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models.Int J Radiat Oncol Biol Phys2019
30413807Quantification of bone flare on <sup>18</sup>F-NaF PET/CT in metastatic castration-resistant prostate cancer.Prostate Cancer Prostatic Dis2019
30413661<sup>18</sup>F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.J Nucl Med2019
29168082A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas.J Neurooncol2018
29916085<sup>18</sup>F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.EJNMMI Res2018
29414505Inter-operator variability in compartmental kinetic analysis of <sup>18</sup>F-fluoromisonidazole dynamic PET.Clin Imaging2018
29572254PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.J Nucl Med2018
29715301TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC).PLoS One2018
29626123<sup>11</sup>C-Choline Pharmacokinetics in Recurrent Prostate Cancer.J Nucl Med2018
  • 1 - 50 of 254

Recommended Authors

Bianca A W Hoeben
Radboud University Medical Center
Career Start Year 2010
Number of shared co-authors 6
Vincenzo Paolillo
UT MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 2
Pedram Heidari
Massachusetts General Hospital
Career Start Year 2008
Number of shared co-authors 1
Thomas A Hope
University of California san francisco
Career Start Year 2007
Number of shared co-authors 11
Babak Saboury
Clinical Center
Career Start Year 2006
Number of shared co-authors 5
Pardeep Kumar
National Institute of Mental Health & Neurosciences (NIMHANS)
Career Start Year 2005
Number of shared co-authors 1
Arman Rahmim
BC Cancer Research Institute, University of British Columbia
Career Start Year 2004
Number of shared co-authors 7
Natasja G Lieuwes
Maastricht University
Career Start Year 2003
Number of shared co-authors 6
Esther G C Troost
German Cancer Research Center (DKFZ)
Career Start Year 2003
Number of shared co-authors 9
Albert J Chang
University of California Los Angeles
Career Start Year 2003
Number of shared co-authors 5
Gang Niu
The First Affiliated Hospital of Xi'an Jiaotong University
Career Start Year 1997
Number of shared co-authors 0
Helen A Shih
Massachusetts General Hospital and Harvard Medical School
Career Start Year 1997
Number of shared co-authors 2
Ronald Boellaard
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Career Start Year 1996
Number of shared co-authors 11
Johan Bussink
Radboud University, Nijmegen Medical Centre
Career Start Year 1995
Number of shared co-authors 9
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 1
Kevin Camphausen
National Cancer Institute
Career Start Year 1994
Number of shared co-authors 2
Ir??ne Buvat
Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO
Career Start Year 1993
Number of shared co-authors 6
Frank P DiFilippo
Cleveland Clinic
Career Start Year 1992
Number of shared co-authors 1
Stefan K??nemann
Switzerland Ecole Polytechnique Federal de Lausanne, EPFL
Career Start Year 1991
Number of shared co-authors 0
Magnus Dahlbom
David Geffen School of Medicine, university of california los angeles
Career Start Year 1988
Number of shared co-authors 1
Johannes Czernin
university of california los angeles
Career Start Year 1987
Number of shared co-authors 5
Curtis B Caldwell
Sunnybrook Research Institute
Career Start Year 1986
Number of shared co-authors 2
John J Sunderland
University of Iowa
Career Start Year 1986
Number of shared co-authors 6
Peter Hoskin
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 5
Jiahe Tian
First Medical Center of Chinese PLA General Hospital
Career Start Year 1982
Number of shared co-authors 0
Andrzej Niemierko
Massachusetts General Hospital
Career Start Year 1982
Number of shared co-authors 2
James R Bading
City of Hope National Medical Center
Career Start Year 1982
Number of shared co-authors 0
John P Kirkpatrick
Duke University Medical Center
Career Start Year 1978
Number of shared co-authors 1
Albert J van der Kogel
University of Wisconsin School of Medicine and Public Health
Career Start Year 1974
Number of shared co-authors 6
Peter S Conti
Keck School of Medicine of USC
Career Start Year 1971
Number of shared co-authors 3

Collaborators

Heiko Sch??der
Memorial Sloan Kettering Cancer Center
Co-authored papers 43
Neeta Pandit-Taskar
Memorial Sloan Kettering Cancer Center
Co-authored papers 22
Milan Grkovski
Memorial Sloan Kettering Cancer Center
Co-authored papers 20
Nancy Y Lee
Memorial Sloan Kettering Cancer Center
Co-authored papers 19
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 17
Mithat Gonen
Co-authored papers 16
Chaitanya Divgi
Columbia University Medical Center Kreitchman PET Center
Co-authored papers 14
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 13
Lloyd J Old
Ludwig Institute for Cancer Research
Co-authored papers 9
Mark M Souweidane
New York Presbyterian and Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Stephen B Solomon
Memorial Sloan-Kettering Cancer Center
Co-authored papers 7
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Tinsu Pan
University of Texas MD Anderson Cancer Center
Co-authored papers 5
Nadeem Riaz
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Simon N Powell
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Jeremy C Durack
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Amita Shukla-Dave
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Stephanie A Harmon
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Peter L Choyke
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Alan L Ho
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
David G Pfister
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Madhu Mazumdar
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Krishna Juluru
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Mathieu Hatt
INSERM
Co-authored papers 2
Jeffrey P Greenfield
Weill Cornell Medical Center, NewYork Presbyterian Hospital
Co-authored papers 2
Nora Katabi
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Juri G Gelovani
Karmanos Cancer Institute (KCI), Wayne State University
Co-authored papers 2
Sean M McBride
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Martin W Brechbiel
National Institutes of Health
Co-authored papers 2
Release 1.2